PUNE: The Phase III human clinical trial of the Covid-19 vaccine being developed by the University of Oxford and manufactured by the Serum Institute of India (SII), began at the state-run Sassoon General Hospital here in Maharashtra On Monday, a senior official said.
“We have started phase III trials of the vaccine (Covishield candidate). We will dose 150 to 200 volunteers,” said Dr. Muralidhar Tambe, Dean of Sassoon General Hospital.
In phase II, trials were carried out at Bharti Vidyapeeth Medical College and also at the city’s KEM hospital.
IBS has partnered with British-Swedish pharmaceutical company AstraZeneca to manufacture the Covid-19 candidate vaccine, which is being developed by the University of Oxford.
Earlier this month, IBS had halted clinical trials of the candidate vaccine in the country.
The Comptroller General of Drugs of India (DCGI) had ordered the SII on September 11 to suspend any new recruitment in the phase II and III clinical trial of the vaccine until further requests after AstraZeneca halted trials in other countries due to to “an unexplained illness” in a study participant.
However, on September 15, the DCGI gave IBS permission to resume the clinical trial of the vaccine.
“We have started phase III trials of the vaccine (Covishield candidate). We will dose 150 to 200 volunteers,” said Dr. Muralidhar Tambe, Dean of Sassoon General Hospital.
In phase II, trials were carried out at Bharti Vidyapeeth Medical College and also at the city’s KEM hospital.
IBS has partnered with British-Swedish pharmaceutical company AstraZeneca to manufacture the Covid-19 candidate vaccine, which is being developed by the University of Oxford.
Earlier this month, IBS had halted clinical trials of the candidate vaccine in the country.
The Comptroller General of Drugs of India (DCGI) had ordered the SII on September 11 to suspend any new recruitment in the phase II and III clinical trial of the vaccine until further requests after AstraZeneca halted trials in other countries due to to “an unexplained illness” in a study participant.
However, on September 15, the DCGI gave IBS permission to resume the clinical trial of the vaccine.
.
